Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

October 18, 2000 8:30-8:45. Problem Solving with FDG Positron Emission Mammography.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2001
Same author

Coarsening of a class of driven striped structures

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2001
Same author

Endogenous interleukin 6 production protects against histopathologic damage in a murine model of ischemia/reperfusion injury.

Current surgery·2000
Same author

Influence of environmental conditions on the activity of the recombinant mannuronan C-5-epimerase AlgE2.

Enzyme and microbial technology·2000
Same author

Anharmonicity of potentials of atoms in potassium hydrogensulfide (KDS) determined by neutron single-crystal diffraction

Acta crystallographica. Section B, Structural science·2000
Same author

Continuous quantum measurement and the emergence of classical chaos

Physical review letters·2000

Related Experiment Video

Updated: Jul 23, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

Antiphospholipid Antibody Syndrome.

Jacobs1, Levine

  • 1Wayne State University School of Medicine, Department of Neurology, University Health Center, 8C, 4201 St. Antoine, Detroit, MI 48201-2153, USA. bjacobs@med.wayne.edu

Current Treatment Options in Neurology
|November 30, 2000
PubMed
Summary

Diagnosing antiphospholipid antibody syndrome (aPS) after ischemic stroke requires evaluating risk factors and lab results. Treatment strategies vary, with anticoagulation or antiplatelet agents considered, pending further research.

More Related Videos

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions
10:58

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions

Published on: July 27, 2017

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Related Experiment Videos

Last Updated: Jul 23, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions
10:58

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions

Published on: July 27, 2017

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Area of Science:

  • Neurology
  • Rheumatology
  • Hematology

Background:

  • Antiphospholipid antibody syndrome (aPS) is a condition that can cause blood clots, leading to ischemic stroke or transient ischemic attack (TIA).
  • Accurate diagnosis involves assessing clinical presentation, vascular risk factors, and laboratory findings, such as anticardiolipin antibody titers and lupus anticoagulant presence.

Purpose of the Study:

  • To guide the diagnostic and therapeutic approach for patients with ischemic stroke or TIA when antiphospholipid antibody syndrome (aPS) is suspected.
  • To highlight the current lack of definitive randomized controlled trial data for stroke prevention in aPS.

Main Methods:

  • Review of diagnostic criteria and risk factor assessment for aPS in stroke patients.
  • Discussion of therapeutic options including anticoagulation and antiplatelet agents based on clinical and laboratory evidence.
  • Emphasis on the need for close follow-up and consideration of future randomized controlled trials.

Main Results:

  • A higher suspicion for aPS is warranted with fewer vascular risk factors and strong laboratory confirmation (high titers, lupus anticoagulant).
  • Therapeutic strategies range from short-term anticoagulation (INR 2.0-3.0) to antiplatelet agents, depending on individual patient factors.
  • A conservative approach with antiplatelet therapy may be suitable for patients with less definitive aPS evidence.

Conclusions:

  • The diagnostic confidence of aPS increases with fewer vascular risk factors and more robust laboratory findings.
  • Treatment decisions for stroke prevention in aPS should be individualized, considering the balance of thrombosis risk and treatment risks.
  • Further randomized controlled trials are needed to establish optimal long-term stroke prevention strategies for aPS.